logo-loader
RNS
viewConvaTec Group PLC

Scrip Dividend - Total Issued Shares

/**/ p{margin-top:0cm;margin-right:0cm;margin-bottom:18.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";} .f{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.f{}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.ba{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 144.0pt; margin-right: 0cm; margin-top: 0cm}span.ay{font-size:14.0pt;font-family:"Arial","sans-serif";color:#31849B}p.bb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}span.aw{font-size:14.0pt; font-family:"Arial","sans-serif";color:#31849B}span.au{font-size:10.0pt; font-family:"Arial","sans-serif";color:#3F3F3F}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%; margin-bottom: 0cm}span.at{font-size:10.0pt;line-height:115%;font-family: "Arial","sans-serif";color:#3F3F3F} p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 106%; text-align: justify; text-justify: inter-ideograph}span.ar{font-size:10.0pt;line-height:106%;font-family: "Arial","sans-serif"}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;text-justify:inter-ideograph}span.ap{font-size:10.0pt;line-height:107%;font-family:"Arial","sans-serif"; color:#404040}span.an{font-size:10.0pt; line-height:107%;font-family:"Tahoma","sans-serif";color:black}span.am{font-size:10.0pt; line-height:107%;font-family:"Arial","sans-serif";color:#404040}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:115%}span.al{font-size: 10.0pt;line-height:115%;font-family:"Arial","sans-serif";color:#404040}span.aj{font-size:10.0pt;line-height:107%;font-family:"Arial","sans-serif"}span.ai{font-size:10.0pt; line-height:107%;font-family:"Arial","sans-serif";color:#0563C1} p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:9.0pt;text-align:justify;text-justify: inter-ideograph;line-height:14.0pt}span.ah{font-size:10.0pt;font-family: "Arial","sans-serif";color:#404040}table.bh{width:480.8pt;margin-left:-5.4pt;border-collapse:collapse}td.ae{width:308.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;text-align:justify;text-justify: inter-ideograph;line-height:14.0pt}td.ab{width:151.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 14.0pt; margin-bottom: 6.0pt; margin-left: 0cm; margin-right: .75pt; margin-top: 0cm; text-align: right; text-indent: 23.25pt}span.ad{font-size:10.0pt;font-family:"Arial","sans-serif"; color:#404040}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 14.0pt; margin-bottom: 6.0pt; margin-left: 16.15pt; margin-right: 0cm; margin-top: 0cm; text-align: right}span.aa{font-size:10.0pt;font-family:"Arial","sans-serif";color:#404040} p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 14.0pt; margin-bottom: 6.0pt; text-align: right}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;text-align:justify;text-justify: inter-ideograph;text-indent:-5.25pt;line-height:14.0pt}p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;line-height:14.0pt}span.v{font-size:10.0pt;font-family:"Arial","sans-serif"}p.bo{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;text-indent:-5.25pt;line-height:14.0pt}p.bp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: 14.0pt}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-23.55pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-right:-23.6pt;text-align:justify;text-justify: inter-ideograph}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -23.55pt; margin-top: 0cm; text-align: justify; text-justify: inter-ideograph}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: 115%} span.o{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:#404040}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;line-height:115%}span.l{font-size:10.0pt; line-height:115%;font-family:"Helvetica","sans-serif";color:blue}span.k{font-size:10.0pt;line-height:107%;font-family: "Arial","sans-serif";color:#3F3F3F}span.j{font-size:10.0pt;line-height:107%;font-family: "Arial","sans-serif";color:#404040}span.i{font-size:10.0pt;line-height:115%;font-family:"Arial","sans-serif"; color:#3F3F3F}span.h{font-size:10.0pt;line-height: 115%;font-family:"Arial","sans-serif";color:#404040;text-decoration:none}p.g{ margin-bottom: 0cm; text-align: center} /**/
RNS Number : 0196O
ConvaTec Group PLC
27 September 2019
 

 

         ConvaTec Group Plc

 

Scrip Dividend - total issued shares

 

 

Reading, United Kingdom (27 September 2019)

On 31 July 2019, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.717 cents per share (the "interim dividend"). This interim dividend is to be paid on 17 October 2019 to shareholders on the share register as at 6 September 2019 ("record date"). The dividend is payable in cash in sterling to holders of ordinary shares. On 1 August 2019, the Company announced that a scrip dividend would be made available for this interim dividend allowing shareholders to elect to receive their dividend in the form of new ordinary shares. The calculation price for the scrip dividend was announced on 12 September 2019.

It is confirmed that 6,159,842 ordinary shares of 10 pence each will be allotted and issued on 17 October 2019 by the Company to those shareholders who elected to receive the scrip dividend alternative. The shares will rank pari passu with the existing issued ordinary shares of the Company. Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List and to the London Stock Exchange for the shares to be admitted to trading.

Dealings in the shares issued under the scrip dividend scheme is expected to commence on 17 October 2019.

 

Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.

TIMETABLE

Key dates in respect of the scrip dividend scheme for the interim dividend are:

Ex-dividend Date

   5 September 2019

Record Date

6 September 2019

Scrip calculation price determined

5-11 September 2019 (inclusive)

Scrip calculation price available and announced

12 September 2019

Mandate delivery deadline for Shares held in uncertificated form

3.00 p.m. on 23 September 2019

Mandate delivery deadline for Shares held in certificated form

5.00 p.m. on 23 September 2019

  Announcement of the total amount of new shares to be issued

                      27 September 2019

  Dividend payment date

                           17 October 2019

  Dispatch of statement in accordance with section 7 of Scheme

                           17 October 2019

Rules and share certificates, CREST accounts credited/updated,

and first day of dealings in New Shares

                                                                                                                                               

Enquiries

 

Analysts, Investors and Media

 

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Mark Reynolds, Director Investor Relations, ConvaTec                 +44 (0)7551 036 625

[email protected]

Alastair Elwen, Finsbury                                                                  +44 (0)207 251 3801

 

Legal Entity Identifier Code:   213800LS272L4FIDOH92

 

About ConvaTec

 

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 

 

# # #

END

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DIVLLFLEARIDFIA

Quick facts: ConvaTec Group PLC

Price: 209.7

Market: LSE
Market Cap: £4.16 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE